NeuroTechR3

What NeuroTechR3 does

NeuroTechR3, Inc. is a privately held, women-owned biomedical device and digital health company founded in April 2020 in Warren, New Jersey, that develops AI-driven neurorehabilitation technologies for individuals recovering from brain injury. The company's core product, R3THA (Rehabilitation Technologies for Hand and Arm), is an AI-powered platform that combines adaptive exergames, markerless motion tracking via the Ultraleap infrared camera, and real-time biofeedback to improve gross and fine motor hand and arm function in patients with stroke, cerebral palsy, and other neurological conditions. The platform includes a HIPAA-compliant therapist portal for remote patient monitoring, a telerehabilitation module for virtual therapy delivery, and cloud-based kinematic analytics that track range of movement, speed, and accuracy over time. Clinical validation is supported by a peer-reviewed publication in the Sensors journal (August 2024) and outcomes data showing 20% improvement in Box and Block Test, 13.6% in Fugl-Meyer Assessment Upper Extremity, and 15.2% in Action Research Arm Test after three months of R3THA use in individuals 6 months to 17 years post-stroke.

The company operates a multi-channel go-to-market combining enterprise clinical subscriptions to rehabilitation hospitals and outpatient centers, direct-to-consumer or clinician-prescribed home subscriptions for continued therapy, and non-dilutive government research grants (NSF SBIR/STTR, NIDILRR SBIR, NJ CSIT). Pricing follows a subscription model with one-time setup fees and monthly or annual billing that automatically renews, with annual price escalators tied to CPI or 3%, whichever is greater. Strategic clinical partnerships with Kessler Foundation, Brooks Rehabilitation, JFK Johnson Rehabilitation Institute, Intensive Therapeutics, Rutgers University, and NJIT support research, validation, and pilot deployments. Customer segments include rehabilitation hospitals and outpatient centers, patients with neurological conditions (both pediatric and adult), and occupational and physical therapists seeking objective outcome measurement and scalable engagement tools. The company is led by co-founders Mee Eriksson (CEO), Dr. Qinyin Qiu (CSO, also a Rutgers assistant professor), Amanda (CTO), and Ashley MontJohnson (Chief Innovation Officer), supported by a clinical advisory board.

The business is pre-commercial to early commercial stage: it has secured roughly $421,000 in disclosed non-dilutive grant funding plus undisclosed Phase II amounts, operates with 1–10 employees, and generates revenue primarily through pilot-stage enterprise subscriptions and home subscriptions. The company has no disclosed private equity or venture capital rounds, no disclosed revenue figures, and no patent portfolio, and relies on third-party Ultraleap hardware for its motion capture layer. Market opportunity is anchored in the projected growth of the global neurorehabilitation market from $1.09B (2020) to $2.45B (2030) and the telerehabilitation market reaching $9.13B by 2027, against a U.S. incidence of approximately 856,000 strokes per year with up to 60% of survivors experiencing chronic upper-extremity impairment.

Name

NeuroTechR3

Legal name

NeuroTechR3, Inc.

Website

http://www.neurotechr3.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

NeuroTechR3 is a privately held digital health company developing R3THA, an AI-driven neurorehabilitation platform using adaptive exergames and markerless motion tracking to improve hand and arm function in stroke and cerebral palsy patients. It sells enterprise clinical subscriptions and home subscriptions across the U.S.

Ownership category

akta.pro rank

Product category

AI-driven neurorehabilitation software

NAICS

Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Services for the Elderly and Persons with Disabilities (62412)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Services-Home Health Care Services (8082)

akta.pro primary industry

Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ)

akta.pro secondary industries

Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG), Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms (HLALABAK), Post-Acute, Rehabilitation & Home Recovery Monitoring (PT/OT, post-surgical) (HLALAFAE)

Keywords

• AI neurorehabilitation platform
• Adaptive exergaming therapy
• Markerless motion tracking
• Telerehabilitation software
• Hand and arm recovery

Headquarters

HQ city

Newark

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

1. Enterprise Sales - Subscriptions and Licensing: Recurring subscription revenue from rehabilitation hospitals, outpatient centers, and clinical networks. Pricing based on Order Form with setup fees and monthly/annual subscriptions. Multiple seat licenses available for clinical use.
2. Home Subscription: Direct-to-consumer or clinician-prescribed home rehabilitation subscription model enabling continued therapy outside clinical settings with progress tracking.
3. Government Research Grants: Non-dilutive SBIR/STTR funding from NIH/NIDILRR and NSF supporting R&D. Phase I grants of $100,000 and Phase II grants of approximately $287,500 per year.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

NeuroTechR3 develops and sells R3THA, an AI-driven neurorehabilitation platform that uses adaptive exergames, markerless motion tracking via an Ultraleap infrared camera, and real-time biofeedback to support hand and arm recovery for patients with stroke, cerebral palsy, and other neurological conditions. The platform is deployed in clinics, at home, and through telerehabilitation, and includes a HIPAA-compliant therapist portal and cloud-based kinematic progress tracking. The company monetizes through enterprise subscriptions/licensing to rehabilitation providers and a direct home subscription offering.

Product overview

NeuroTechR3 offers a unified AI-driven neurorehabilitation platform called R3THA (Rehabilitation Technologies for Hand and Arm), designed to improve hand and arm function for individuals with neurological conditions. The core R3THA platform combines adaptive exergames with markerless motion tracking (via Ultraleap infrared camera) and real-time biofeedback. This platform is augmented by the HIPAA-compliant R3THA Therapist Portal module, which provides remote monitoring, telehealth/telerehabilitation capabilities, and cloud-based progress analytics. The system supports use across clinical settings, home-based therapy, and telerehabilitation, with the platform automatically adapting difficulty based on patient performance.

Differentiator

Problem solved

Functional benefit

Products and services

• R3THA (Rehabilitation Technologies for Hand and Arm) AI-driven neurorehabilitation platform combining adaptive exergames, markerless motion tracking via an Ultraleap infrared camera, and real-time biofeedback to enhance hand and arm function for patients with stroke, cerebral palsy, and other neurological conditions. Designed for clinical, home, and telerehabilitation use, with cloud-based progress tracking. Sold via enterprise subscriptions/licensing to rehabilitation providers and a direct home subscription program.
• R3THA Enterprise Clinical Subscription Subscription-based enterprise license for rehabilitation hospitals, outpatient centers, and clinical networks to use R3THA in clinical settings. Includes setup fee, monthly recurring subscription based on the Order Form, multiple seat licenses, and is automatically renewed monthly with annual price adjustments tied to CPI or 3%.
• R3THA Home Subscription Program Patient-facing subscription program for continued upper extremity rehabilitation at home, available direct-to-consumer or prescribed by clinicians, enabling independent therapy exercises and ongoing progress tracking between clinical visits.
• R3THA Read-Only Transition Subscription Read-only subscription tier available to enterprise customers during a transition period after termination of their primary R3THA subscription. Priced at $200 or 20% of the average of the last three months' invoices, whichever is higher.

Quantifiable outcome

• 20% improvement in Box and Block Test (BBT), 13.6% in Fugl-Meyer Assessment Upper Extremity (FMA-UE), 15.2% in Action Research Arm Test (ARAT) after 3 months of use in individuals 6 months to 17 years post-stroke

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core and strategic.

• Kessler FoundationcoreStrategic or Co-development Partner · 19 June 2024Research collaboration with Kessler Foundation, a nationally recognized leader in rehabilitation research. Primary Investigator Dr. Kiran K. Karunakaran leads a study at Kessler Foundation to accelerate clinical validation and demonstrate feasibility of R3THA in diverse settings for stroke recovery. The collaboration aims to enhance development and deployment of NeuroTechR3's rehabilitation system and opens doors to further research opportunities.
• Rutgers UniversitycoreStrategic or Co-development PartnerCollaboration with Rutgers University advances clinical research, rehabilitation science, and workforce development in neurorehabilitation. Partnerships with faculty, clinicians, and students support clinical studies, usability evaluations, and translational research focused on improving upper-extremity rehabilitation outcomes. Provides insights into patient needs, therapy delivery, and evidence-based rehabilitation practices.
• New Jersey Institute of Technology (NJIT)coreStrategic or Co-development PartnerNeuroTechR3 was founded on technology and research developed through collaborations with NJIT researchers. The university continues as an important innovation partner supporting advances in biomedical engineering, artificial intelligence, movement analytics, machine learning, and digital health. Advancing technologies for personalized rehabilitation and objective outcome measurement.
• Intensive TherapeuticscoreStrategic or Co-development PartnerPartnership with Intensive Therapeutics, a leader in specialized rehabilitation services for children with neurological and developmental conditions. Through collaboration with clinicians, patients, and families, evaluated usability, feasibility, and effectiveness of R3THA in pediatric rehabilitation settings including Camp Helping Hands program.
• Brooks RehabilitationstrategicStrategic or Co-development PartnerCollaboration with Brooks Rehabilitation, one of the nation's leading rehabilitation healthcare systems, to explore how technology-enabled rehabilitation can support patients across the continuum of care from inpatient through outpatient therapy and home-based recovery. Investigating opportunities to enhance patient engagement, increase therapy intensity, and improve continuity of care.
• JFK Johnson Rehabilitation InstitutestrategicStrategic or Co-development PartnerCollaboration with JFK Johnson Rehabilitation Institute, one of the nation's premier rehabilitation centers. Clinicians and rehabilitation specialists evaluate emerging rehabilitation technologies, gather clinical feedback, and explore innovative approaches to improving upper-extremity recovery and patient engagement.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Constant Therapy Health: Digital cognitive and speech/neurological rehabilitation platform serving stroke and TBI patients with clinician dashboards and home exercise programs. Directly comparable to R3THA as a subscription-based neurorehab SaaS targeting the same patient populations and clinician buyers.
• Saebo: Manufacturer of upper-extremity rehabilitation devices and digital tools for stroke survivors, sold through hospitals, clinics, and D2C. Comparable as a device-plus-software stroke rehab company serving overlapping clinical buyers and patient populations.
• Flint Rehabilitation Devices: Developer of MusicGlove and other hand/arm rehabilitation devices with sensor-based, gamified therapy for stroke survivors. Directly comparable to R3THA in target indication (hand/arm stroke rehab), gamified therapy approach, and D2C plus clinical channels.
• Neofect: Maker of smart rehabilitation devices (e.g., Rapael Smart Glove, NeoMano) and gamified therapy software for stroke and neurological patients. Comparable to R3THA in combining hardware sensors with adaptive, game-based upper-extremity therapy for neurorehab.
• Bionik Laboratories: Robotic and digital rehabilitation technology provider focused on upper-extremity recovery for stroke patients. Directly comparable as a device/software neurorehab company pursuing similar hospital channel sales and clinical outcomes.
• Motus Nova: Robotic hand and arm rehabilitation device company targeting stroke survivors with clinical and home use. Comparable to R3THA in focusing on hand/arm upper-extremity stroke rehabilitation with a tech-enabled therapy model.
• Reflexion Health: Digital therapeutics company offering VERA, a FDA-cleared virtual exercise rehabilitation assistant for physical therapy, including neurological indications. Comparable to R3THA as a digital, home-and-clinic neurorehabilitation platform sold to enterprise clinical customers.

Broad incumbents

• MindMaze: Digital neurotherapeutics company combining VR, motion tracking, and AI for stroke, brain injury, and neurorehabilitation, with FDA-cleared products and broader clinical scope. Comparable as a broader, better-funded incumbent in AI-driven neurorehab; competes for the same enterprise hospital buyers.
• Hinge Health: Large digital musculoskeletal therapy platform combining sensor-based exercise, coaching, and AI for MSK conditions, sold to employers and health plans. Comparable as a digital rehab platform with home exercise and remote monitoring, though focused on MSK rather than neuro; serves as a benchmark for scaling a digital rehab subscription business.
• Sword Health: AI-powered digital musculoskeletal and pelvic health therapy platform with wearable motion sensors and remote clinician oversight. Comparable to R3THA in the digital rehab + motion-tracking subscription model, though focused on MSK pain rather than neurological conditions; represents a broader incumbent scaling a similar tech-enabled care delivery model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/neurotechr3
• LinkedInlinkedin.com/company/neurotechr3
• Instagraminstagram.com/neurotechr3
• Xx.com/neurotechr3

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroTechR3